The Role of Stereotactic Frame-Based Biopsy for Brainstem Tumors in the Era of Molecular-Based Diagnosis and Treatment Decisions

• Published in: Current oncology (Toronto) 2022-06, Vol.29 (7), p.4558-4565
• Main Authors: Hirano, Yudai, Shinya, Yuki, Aono, Toshiya, Hasegawa, Hirotaka, Kawashima, Mariko, Shin, Masahiro, Takami, Hirokazu, Takayanagi, Shunsaku, Umekawa, Motoyuki, Ikemura, Masako, Ushiku, Tetsuo, Taoka, Kazuki, Tanaka, Shota, Saito, Nobuhito
• Format: Article
• Language: English
• Subjects: brainstem tumor; frame-based; stereotactic biopsy
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol29070360

Stereotactic frame-based brain tumor biopsy (SFB) is a potent diagnostic tool considering its minimal invasiveness, though its diagnostic power and safety for brainstem lesions remain to be discussed. Here, we aimed to examine the usefulness of SFB for brainstem tumors. Twenty-two patients with brainstem tumors underwent 23 SFBs at our institution during 2002–2021. We retrospectively analyzed patient characteristics, tumor pathology, surgical procedures, and outcomes, including surgery-related complications and the diagnostic value. Seven (32%) tumors were located from the midbrain to the pons, eleven (50%) in the pons only, and four (18%) from the pons to the medulla oblongata. The target lesions were in the middle cerebellar peduncles in sixteen procedures (70%), the cerebellum in four (17%), the inferior cerebellar peduncles in two (9%), and the superior cerebellar peduncles in one (4%). A definitive diagnosis was made in 21 patients (95%) at the first SFB. The diagnoses were glioma in seventeen (77%) cases, primary central nervous system lymphoma in four (18%), and a metastatic brain tumor in one (5%). The postoperative complications (cranial nerve palsy in three [13%] cases, ataxia in one [4%]) were all transient. SFB for brainstem tumors yields a high diagnostic rate with a low risk of morbidity.